Immunocore Holdings (IMCR) Receivables - Other (2019 - 2022)

Immunocore Holdings has disclosed Receivables - Other across 4 years of filings, most recently posting $9.0 million for Q4 2022.

• Receivables - Other for Q4 2022 came in at $9.0 million, up 354.71% year-over-year; the trailing twelve-month figure through Dec 2022 was $9.0 million (up 354.71% YoY), and the FY2022 annual result was $9.0 million, up 345.5% from the prior year.
• Receivables - Other came in at $9.0 million for Q4 2022 at Immunocore Holdings, up from $2.0 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $9.0 million in Q4 2022 to a low of $2.0 million in Q4 2021.
• The 4-year median for Receivables - Other is $3.5 million (2019), against an average of $4.5 million.
• Across the five-year window, Receivables - Other plunged 51.77% in 2020 and surged 354.71% in 2022, its largest moves.
• Immunocore Holdings' Receivables - Other stood at $4.7 million in 2019, then slumped by 51.77% to $2.3 million in 2020, then retreated by 12.85% to $2.0 million in 2021, then soared by 354.71% to $9.0 million in 2022.
• The last three Receivables - Other figures came in at $9.0 million (Q4 2022), $2.0 million (Q4 2021), and $2.3 million (Q4 2020), per Business Quant data.